Literature DB >> 21968616

Potent inhibitory effect of the cyclolignan picropodophyllin (PPP) on human adrenocortical carcinoma cells proliferation.

Mabrouka Doghman, Magnus Axelson, Enzo Lalli.   

Abstract

Adrenocortical carcinoma (ACC) is a very aggressive tumor with a poor prognosis. Available treatments for this type of cancer are far from being satisfactory. The IGF signalling pathway represents an important mechanism for ACT growth and constitutes a relevant therapeutic target. We investigated the effect of picropodophyllin (PPP), a member of the cyclolignan family and a new inhibitor of IGF-1R, on proliferation of human adrenocortical cell lines H295R and SW-13. PPP inhibits proliferation and induces an important accumulation in G2/M phase and apoptosis of H295R and SW-13 cells. Our data suggest that PPP may be a promising candidate for drug development for adrenocortical carcinoma.

Entities:  

Year:  2011        PMID： 21968616      PMCID： PMC3180063     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN： 2156-6976            Impact factor:   6.166


  21 in total

1.  Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors.

Authors:  Mabrouka Doghman; Abeer El Wakil; Bruno Cardinaud; Emilie Thomas; Jinling Wang; Wei Zhao; Maria Helena C Peralta-Del Valle; Bonald C Figueiredo; Gerard P Zambetti; Enzo Lalli
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

2.  Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model.

Authors:  Michaela Luconi; Monica Mangoni; Stefania Gelmini; Giada Poli; Gabriella Nesi; Michela Francalanci; Nicola Pratesi; Giulia Cantini; Adriana Lombardi; Monica Pepi; Tonino Ercolino; Mario Serio; Claudio Orlando; Massimo Mannelli
Journal:  Endocr Relat Cancer       Date:  2010-02-18       Impact factor: 5.678

Review 3.  Emerging drugs for adrenocortical carcinoma.

Authors:  Alfredo Berruti; Anna Ferrero; Paola Sperone; Fulvia Daffara; Giuseppe Reimondo; Mauro Papotti; Luigi Dogliotti; Alberto Angeli; Massimo Terzolo
Journal:  Expert Opin Emerg Drugs       Date:  2008-09       Impact factor: 4.191

4.  Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth.

Authors:  Ada Girnita; Leonard Girnita; Fabrizio del Prete; Armando Bartolazzi; Olle Larsson; Magnus Axelson
Journal:  Cancer Res       Date:  2004-01-01       Impact factor: 12.701

5.  Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.

Authors:  Ferdous M Barlaskar; Aaron C Spalding; Joanne H Heaton; Rork Kuick; Alex C Kim; Dafydd G Thomas; Thomas J Giordano; Edgar Ben-Josef; Gary D Hammer
Journal:  J Clin Endocrinol Metab       Date:  2008-10-14       Impact factor: 5.958

Review 6.  Adrenocortical cancer: pathophysiology and clinical management.

Authors:  Rossella Libè; Amato Fratticci; Jérôme Bertherat
Journal:  Endocr Relat Cancer       Date:  2007-03       Impact factor: 5.678

7.  Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis.

Authors:  Thomas J Giordano; Dafydd G Thomas; Rork Kuick; Michelle Lizyness; David E Misek; Angela L Smith; Donita Sanders; Rima T Aljundi; Paul G Gauger; Norman W Thompson; Jeremy M G Taylor; Samir M Hanash
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

8.  The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells.

Authors:  Mabrouka Doghman; Julie Cazareth; Enzo Lalli
Journal:  J Clin Endocrinol Metab       Date:  2008-06-10       Impact factor: 5.958

9.  Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists.

Authors:  Mabrouka Doghman; Julie Cazareth; Dominique Douguet; Franck Madoux; Peter Hodder; Enzo Lalli
Journal:  J Clin Endocrinol Metab       Date:  2009-03-24       Impact factor: 5.958

10.  Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors.

Authors:  C Gicquel; X Bertagna; H Schneid; M Francillard-Leblond; J P Luton; F Girard; Y Le Bouc
Journal:  J Clin Endocrinol Metab       Date:  1994-06       Impact factor: 5.958
View more
  5 in total

1.  Elucidating the Role of the Maternal Embryonic Leucine Zipper Kinase in Adrenocortical Carcinoma.

Authors:  Katja Kiseljak-Vassiliades; Yu Zhang; Adwitiya Kar; Raud Razzaghi; Mei Xu; Katherine Gowan; Christopher D Raeburn; Maria Albuja-Cruz; Kenneth L Jones; Hilary Somerset; Lauren Fishbein; Stephen Leong; Margaret E Wierman
Journal:  Endocrinology       Date:  2018-07-01       Impact factor: 4.736

2.  Expression of STAT3 and IGF2 in adrenocortical carcinoma and its relationship with angiogenesis.

Authors:  Y Zhu; Y Xu; D Chen; C Zhang; W Rui; J Zhao; Q Zhu; Y Wu; Z Shen; W Wang; G Ning; X Wang
Journal:  Clin Transl Oncol       Date:  2013-11-01       Impact factor: 3.405

Review 3.  Pediatric adrenocortical tumors: what they can tell us on adrenal development and comparison with adult adrenal tumors.

Authors:  Enzo Lalli; Bonald C Figueiredo
Journal:  Front Endocrinol (Lausanne)       Date:  2015-02-18       Impact factor: 5.555

Review 4.  Diagnostic and prognostic features in adrenocortical carcinoma: a single institution case series and review of the literature.

Authors:  Kerollos N Wanis; Rani Kanthan
Journal:  World J Surg Oncol       Date:  2015-03-24       Impact factor: 2.754

5.  PDGFR and IGF-1R Inhibitors Induce a G2/M Arrest and Subsequent Cell Death in Human Glioblastoma Cell Lines.

Authors:  Estefania Carrasco-Garcia; Isabel Martinez-Lacaci; Leticia Mayor-López; Elena Tristante; Mar Carballo-Santana; Pilar García-Morales; Maria Paz Ventero Martin; Maria Fuentes-Baile; Álvaro Rodriguez-Lescure; Miguel Saceda
Journal:  Cells       Date:  2018-09-06       Impact factor: 6.600
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.